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Abstract
Traditional vaccines consisting of live attenuated pathogens or inactivated toxins cannot
be readily applied to the more challenging diseases of the present e.g. hepatitis C and the
human immunodeficiency virus. As such, there is a need to develop new methods of
priming the immune system against such foreign invaders. Recombinant protein subunits
and peptides are relatively safe alternatives to live attenuated pathogens. However, these
antigens are poorly immunogenic when administered alone in solution form and thus
require the use of an adjuvant. To this end, we have developed a hydrogel-based
nanoparticulate system to encapsulate protein antigen and to co-deliver it with
DNA/RNA-based adjuvants to dendritic cells, the key antigen presenting cells in primary
immune responses. Using CpG oligonucleotides or siRNA as adjuvants, we observed via
enzyme-linked immunosorbent assays for interleukin 12 and interferon-a, respectively,
that DCs were activated by CpG oligonucleotide- and siRNA-functionalized
nanoparticles -10-fold more potently than by soluble CpG or siRNA ligands.
Thesis Supervisor: Darrell J. Irvine
Title: Assistant Professor of Biomedical Engineering and Materials Science and
Engineering
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1 Introduction
1.1 A brief introduction to vaccines
Vaccines have traditionally consisted of live attenuated pathogens, whole inactivated
organisms or inactivated toxins [1]. While such vaccines are widely used today and have
proven to be efficacious against a wide variety of diseases such as polio, smallpox and
hepatitis B, several constraints have restricted their use against more challenging diseases
such as hepatitis C and the human immunodeficiency virus (HIV) [2].
Live attenuated pathogen vaccines stimulate immunity via a transient infection caused by
a live replicating organism, for example, the smallpox vaccine formulated by Jenner in
1796 [3]. Live attenuated pathogens might revert back to their more virulent forms,
especially in immunosuppressed or immunocompromised individuals. Even if the whole
pathogen were to be inactivated, it may contain highly reactogenic components that may
result in undesirable side effects e.g. anaphylactic shock for the case of Bordetella
pertussis [2]. Beyond that, some organisms are difficult or even impossible to grow in
culture and purify, e.g., the hepatitis C virus and the human papillomavirus, further
hindering attempts at the preparation of clean, safe and effective vaccines [2].
Over the past decade, several new approaches to vaccine development have emerged. In
particular, the use of recombinant protein subunits and synthetic peptides offers
significant advantages over the more traditional vaccines that utilize live attenuated or
11
whole inactivated organisms [2]. Since no potentially virulent organisms are utilized in
the case of the former, there is no risk of possible infection. In addition, recombinant
protein subunits and synthetic peptides offer the benefits of ease of production and
purification, and reduced toxicity. However, such antigens are poorly immunogenic
when administered alone and hence require the use of an adjuvant.
Originally defined by Ramon as "substances used in combination with a specific antigen
that produce more immunity than the antigen alone," immunological adjuvants can also
bias the immune system toward TH1 or TH2 immunity [1], [4]. The only adjuvants
currently approved by the US Food and Drug Administration are aluminum-based salts.
Despite their good safety record, these aluminum-based salts are weak adjuvants for cell-
mediated immunity and have been associated with allergic reactions in some human
subjects [5], [6].
1.2 Targeting dendritic cells
Dendritic cells (DCs) are antigen-presenting cells (APCs) that act as initiators and
modulators of immune responses [7]. DCs are not only one of Nature's most efficient
stimulators of B and T lymphocytes, they are also important for the secretion of various
cytokines such as interleukin 12 (IL-12) and chemokines such as interleukin 8 (IL-8) for
the initiation of an effective adaptive immune response [8] - [11]. They are also
essential in the tolerization of T cells to self-antigens, thus preventing auto-immunity [7].
Once difficult to obtain and study, DCs can now be readily obtained in large numbers,
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thus aiding their study and characterization [12]. Hence, we would like to exploit the
powerful immunostimulatory and immunomodulatory capacities of DCs by creating a
vaccine composed of hydrogel nanoparticles that simultaneously deliver both antigen and
a maturation/activation signal to DCs.
1.3 DNA/RNA danger signals
Despite the discovery of the innate immune system over a century ago by Elie
Metchnikoff, progress in its analysis has been largely overshadowed by the fascinating
intricacies of adaptive immunity [13]. The recent discovery and characterization of the
Toll-like receptor (TLR) family have sparked a renewed interest in the field of innate
immunity -- to date there are eleven members of the TLR family [14]. For our purposes,
we were interested in stimulating DC activation via TLRs. We focused in particular on
TLR 3 and TLR9.
Polyriboinosinic polyribocytidylic acid (poly(I:C)), double-stranded RNA (dsRNA) and
synthetic short-interfering ribonucleic acid (siRNA) have all been shown to activate
TLR3 and to be potent DC activators [15] - [17]. In particular, activation of TLR3
induces DCs to secrete interferon a (IFN-a), a type I interferon that synergizes with other
proinflammatory cytokines to activate innate and adaptive immune effector cells [18],
[19]. IFN-(x also causes cells to enter into an "anti-viral" state, thus aiding in the fight
against viral and bacterial infections. Furthermore, IFN-a secretion might also stimulate
DCs in an autocrine manner to further induce their maturation and activation.
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CpG deoxyribonucleic acid (DNA) oligonucleotides, ligands for TLR9, have been shown
to be robust DC activators [20]. In fact, immunization of mice with antigen and CpG
oligonucleotides co-encapsulated in cationic liposomes elicited enhanced cytokine
secretion by lymphocytes and antibody titers were observed to increase an order of
magnitude compared to that elicited by immunization with soluble antigen [21].
We thus seek to synthesize a particulate protein carrier that would enable us to co-deliver
both antigen and an immunostimulatory danger signal to drive DC maturation and
activation and hence promote a robust immune response. We propose that a two-phase
aqueous miniemulsion polymerization method would allow high levels of protein to be
encapsulated under mild conditions in the absence of organic solvents, thereby preserving
the integrity of the antigen. Starting with near-saturated salt solutions of Pluronic® F-68,
a polyoxyethylene-polyoxypropylene-polyoxyethylene triblock copolymer (PEO-PPO-
PEO), mixed with the model protein antigen, ovalbumin (OVA), and the methacrylate
monomers poly(ethylene glycol) methacrylate (PEGMA), methacrylic acid (MAA), and
poly(ethylene glycol) dimethacrylate (PEGDMA), we hope to achieve phase-separation
of the mixture upon heating. This would then allow us to obtain hydrogel nanoparticles
by free radical polymerization of the monomers around the salted-out OVA. We would
then surface-functionalize the nanoparticles by electrostatic adsorption of either CpG
oligonucleotides or bax siRNA, to provide immunostimulatory signals to DCs.
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These mesoscale particles, which mimic pathogens in size and in their functional co-
delivery of antigen and activation signals, should be avidly phagocytosed by dendritic
cells which would then be rapidly matured and activated. Due to the relatively gentle
nature of this synthetic approach, we anticipate that it may be of utility for higher potency
vaccines and drug delivery applications requiring the delivery of high levels of fragile
proteins.
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2 Experimental
2.1 Materials
Poly(ethylene glycol) methacrylate (PEGMA, -526 Da), poly(ethylene glycol)
dimethacrylate (PEGDMA, -875 Da), methacrylic acid (MAA), poly(L-arginine) (5000 -
15000 Da), Pluronic® F-68 (polyoxyethylene-polyoxypropylene-polyoxyethylene triblock
copolymer, molecular formula: E07 8-PO3 0-EO 78, -8400 Da) and diethyl pyrocarbonate
(DEPC) were purchased from Sigma-Aldrich. Sodium chloride was obtained from
Mallinckrodt Laboratory Chemicals, Inc. Ammonium persulfate (APS) was obtained
from Pierce Biotechnology, Inc. while sodium metabisulfite (SMS) was supplied by
Fluka. DEPC-treated RNase-free water and RNase-free 10X phosphate buffered saline
(PBS) were procured from Ambion®. All reagents were used as received, without further
purification. Unless otherwise specified, RNase-free glassware and reagents were used
for all experiments.
CpG oligonucleotide 1826 (TCC ATG ACG TTC CTG ACG TT) was synthesized by the
MIT Biopolymers Laboratory. bax siRNA (sense strand sequence: GGU GCC GGA
ACU GAU CAG ATT, anti-sense strand sequence: UCU GAU CAG UUC CGG CAC
CTT) was acquired from Integrated DNA Technologies, Inc. Chromatographically-
purified ovalbumin (OVA) was obtained from Worthington Biochemical Corporation
while Texas Red-conjugated ovalbumin (TR-OVA) and DQTM ovalbumin (DQ-OVA)
were purchased from Molecular ProbesTM. Prior to use, endotoxin was removed from
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ovalbumin by the use of Detoxi-Gel AffinityPak Prepacked Columns from Pierce
Biotechnology, Inc., according to the manufacturer's instructions.
DuoSet® enzyme-linked immunosorbent assay (ELISA) development kits for the
quantification of interleukin 12 p40 subunit (IL-12 p40) and interleukin 12 p70 subunit
(IL-12 p70) were obtained from R & D Systems, Inc. Capture and detection antibodies
and interferon-ca (IFN-a) protein standards for IFN-c quantification by ELISA was
purchased from PBL Biomedical Laboratories, Inc. via R & D Systems, Inc.
Roswell Park Memorial Institute (RPMI) 1640 medium was acquired from Gibco®. Non-
essential amino acids, sodium pyruvate, penicillin and streptomycin were provided by
Mediatech, Inc. Fetal bovine serum was obtained Hyclone, Inc. Recombinant murine
granulocyte-macrophage colony stimulating factor (rmGM-CSF) was supplied by R & D
Systems, Inc.
2.2 Hydrogel nanoparticle synthesis
Protein-loaded hydrogel nanoparticles were synthesized by a miniemulsion free-radical
polymerization technique based on the salt precipitation (salting-out) of protein. NaCl
(15 g) was dissolved in a 4% w/v aqueous solution of Pluronic®® F-68 (50 mL) in a
round-bottomed flask. The resultant solution was degassed under N2 for 30 min with
concomitant stirring. OVA (50 mg) was dissolved in PBS (1 mL) and subsequently
added to the Pluronico® F-68-NaCl solution. For the synthesis of fluorescently-labeled
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particles, TR-OVA (250 g) or DQ-OVA (1 mg) was added to the OVA-PBS solution.
PEGMA (300 mg, -5.7 x 10- 4 mol), PEGDMA (15 mg, -1.71 x 10-5 mol) and MAA (15
mg, -1.74 x 10-5 mol) were mixed, degassed under N2 for 5 minutes and added to the
OVA-containing Pluronic"® F-68-NaCl solution, forming a colorless solution. The
addition of OVA and the monomer mixture was carried out with the continued stirring of
the Pluronic"® F-68-NaCl solution and the concomitant purging of N2 through the round-
bottomed flask. The resultant solution was then transferred to a water bath at 400C and
stirred at 600 rpm. As the temperature of the reagent solution equilibrated with that of
the water bath, Pluronic®® F-68 salted-out and resulted in the phase separation formation
of a miniemulsion. Polymerization of the miniemulsion droplets was initiated by the
addition of an aqueous solution of 1% w/w APS/1% w/w SMS (1 mL). The reaction was
allowed to proceed for 5 min, following which water (50 mL) was added to the resultant
suspension of hydrogel nanoparticles. The particles were then collected and purified by
centrifugation and washing with water (3 x 50 mL). Finally, the collected particles were
re-suspended in a 0.4% w/v aqueous solution of Pluronic®® F-68 in PBS (5 mL) to obtain
a stock suspension of particles with a concentration of -10 mg/mL and stored at 4°C until
further use.
2.3 Electrostatic assembly of CpG oligonucleotide on hydrogel nanoparticles
In order to provide a high density of CpG 1826 oligonucleotides, DC-activating ligands,
on the surface of each hydrogel nanoparticle, the initially anionic surface of the hydrogel
particles were modified by the sequential electrostatic adsorption of cationic poly(L-
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arginine) and anionic CpG oligonucleotides. Stock hydrogel particle suspension (1 mL)
was centrifuged, washed and re-suspended in PBS (4 x 1 mL) to obtain a final particle
concentration of 10 mg/mL. The resultant particle suspension was then incubated with
poly(L-arginine) (final concentration: 5 mg/mL) overnight at 37°C. The reaction mixture
was shaken continuously to ensure homogeneous mixing of the particles and any un-
adsorbed poly(L-arginine). The consequent poly(L-arginine)-coated hydrogel particles
were then centrifuged, washed and re-suspended in PBS (5 x 1 mL) to remove any excess
unbound poly(L-arginine). Subsequently, the particles were incubated with CpG
oligonucleotides (final concentration: 100 tiM) for 3 hrs at 370C in PBS, pH 7.4. The
resultant CpG-functionalized particles were centrifuged, washed and re-suspended in
PBS (5 x 1 mL) to remove any excess unbound CpG oligonucleotide. The functionalized
nanoparticles were stored at 4C until further use. After centrifugation, the amount of
unbound CpG oligonucleotide in the supernatant of the CpG-functionalized particle
suspension was determined by the specific absorption of DNA at X = 260 nm. A standard
curve for CpG 1826 oligonucleotide specific absorption at X = 260 nm was determined
and used to estimate the concentration of unbound CpG oligonucleotide in the
previously-mentioned supernatant in Section 2.3. The efficiency of CpG oligonucleotide
coupling was determined as follows:
CpG coupling efficiency = (1- CpG concentration in the supernatant 100% (1)
Initial CpG concentration
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2.4 Electrostatic assembly of bax siRNA on hydrogel nanoparticles
siRNA-functionalized hydrogel nanoparticles were fabricated under RNase-free
conditions. All reagents were either bought RNase-free from Ambion® or treated with
DEPC. All materials were first washed with RNaseZap® from Ambion® and then with
DPEC-treated water to remove any RNase which was present.
In order to provide a high density of bax siRNA molecules, DC-activating ligands, on the
surface of each hydrogel nanoparticle, the initially anionic surface of the hydrogel
particles were modified by the sequential electrostatic adsorption of cationic poly(L-
arginine) and anionic bax siRNA. Stock hydrogel particle suspension (1 mL) was
centrifuged, washed and re-suspended in PBS (4 x 1 mL) to obtain a final particle
concentration of 10 mg/mL. The resultant particle suspension was then incubated with
poly(L-arginine) (final concentration: 5 mg/mL) overnight at 370C. The reaction mixture
was shaken continuously to ensure homogeneous mixing of the particles and any un-
adsorbed poly(L-arginine). The consequent poly(L-arginine)-coated hydrogel particles
were then centrifuged, washed and re-suspended in PBS (5 x 1 mL) to remove any excess
unbound poly(L-arginine). Subsequently, the particles were incubated with bax siRNA
(final concentration: 1 M) for 3 hrs at 370C in PBS, pH 7.4. The resultant siRNA-
functionalized particles were centrifuged, washed and re-suspended in PBS (5 x 1 mL) to
remove any excess unbound siRNA. The functionalized nanoparticles were stored at 40C
until further use. After centrifugation, the amount of unbound siRNA oligonucleotide in
the supernatant of the siRNA-functionalized particle suspension was determined by the
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specific absorption of RNA at = 260 nm. A standard curve for bax siRNA specific
absorption at X = 260 nm was determined and used to estimate the concentration of
unbound bax siRNA in the previously-mentioned supernatant in Section 2.4. The
efficiency of bax siRNA coupling was determined as follows:
siRNA coupling efficiency = siRNA concentration in the supernatant 100% (2)
Initial siRNA concentration
2.5 Hydrogel nanoparticle characterization
2.5.1 Hydrogel nanoparticle size distribution
Hydrogel nanoparticles size distributions were characterized by dynamic light scattering
using a 657 nm laser source at a fixed angle of 90° (Brookhaven 90Plus Particle Sizer).
Typical count rates were 350,000 per second and collection times were 15 min.
2.5.2 Protein/ovalbumin encapsulation efficiency
The amount of protein encapsulated during synthesis was determined as described below.
TR-OVA in fabrication process as described in Section 2.2 and the supematants from
particle syntheses were collected. The fluorescence of the tracer protein, TR-OVA, with
Xex = 584 nm and em = 612 nm) was measured in a spectrofluorometer (Molecular
Devices SpectraMax Gemini Spectrofluorometer) to determine the amount of
unencapsulated Texas TR-OVA by comparing the measured fluorescence to a previously-
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determined standard curve for TR-OVA. The OVA encapsulation efficiency was
calculated as follows:
Encapsul. efficiency = (1- Concentration of TR -OVA in the supernatant x100% (3)
Initial TR -OVA concentration
2.5.3 Enzymatic degradation and release of encapsulated ovalbumin
To assess the in vitro digestion and release of encapsulated OVA by phagolysosomal
proteases, the hydrogel nanoparticles were resuspended at a concentration of -7 mg/mL,
equivalent to -5 mg/mL ovalbumin, in 0.1 M pH 5.5 Glycine-HC1 buffer and incubated
with bovine spleen cathepsin D (final concentration: 200 jtg/mL) for 48 hrs. The sample
was then centrifuged and the supernatant analyzed by size exclusion chromatography
(Hitachi LaChrom D-7000 HPLC system) in PBS using a Superdex200 column
(Amersham Biosciences). Eluting proteins or peptide fragments were analyzed by a UV-
vis detector (Hitachi L-7420) measuring absorbance at 280 nm.
2.6 Bone marrow-derived dendritic cell culture
All animal work was conducted according to institute, state and federal guidelines, using
instituted-approved protocols. Murine bone marrow-derived dendritic cells (BMDCs)
were prepared from bone marrow of C57BL/6 mice (Jackson Laboratories) after the
method of Inaba [12]. Briefly, bone marrow cells from the femurs and tibias were treated
with hypertonic ammonium chloride to lyse red blood cells, and the remaining
progenitors were plated at a density of 1 million cells/well in a 24-well plate in complete
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RPMI 1640 medium, supplemented with 2 mM L-glutamine, 50 [tM 2-mercaptoethanol,
non-essential amino acids, sodium pyruvate, 10% fetal bovine serum and 5 ng/ml rmGM-
CSF. On days 2, 4, and 6 of the culture, 80% of the medium was replaced with fresh
medium containing 5 ng/ml rmGM-CSF. The resultant day 6/day 7 dendritic cells were
used for all experiments.
2.7 Hydrogel nanoparticle uptake by dendritic cells
DCs (1 million/ml) were incubated with DQ-OVA-containing hydrogel nanoparticles (50
jtg/ml OVA) in complete RPMI medium for 1 hour at 370C in complete RPMI medium.
The medium was replaced to remove any free particles and the particles/DCs were
imaged at 40X using the fluorescence system described above. Fluorescence from any
non-internalized particles bound on the surfaces of the DCs was quenched by the addition
of an aqueous solution of 0.4% w/v trypan blue [22].
2.8 Activation and maturation of dendritic cells
2.8.1 CpG-functionalized hydrogel nanoparticles
DCs were plated in 96-well round-bottom tissue culture plates at a density of 1 x 105 cells
per well and incubated for 2 hrs before the addition of CpG-functionalized OVA
hydrogel nanoparticles, unfunctionalized hydrogel nanoparticles and CpG
oligonucleotide. The highest final concentration of CpG oligonucleotide used was 1 M.
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CpG-functionalized nanoparticles were added such that the effective concentrations of
CpG oligonucleotide delivered along with the nanoparticles matched those of the soluble
CpG oligonucleotide controls. Control unfunctionalized nanoparticles were added such
that their final concentrations matched those of the CpG-functionalized nanoparticles.
All samples were incubated for 48 hrs, upon which the culture supernatants were
analyzed for IL-12p40 and IL-12p70, key markers of DC maturation.
2.8.2 bax siRNA-functionalized hydrogel nanoparticles
DCs were plated in 96-well round-bottom tissue culture plates at a density of 2 x 105 cells
per well and incubated for 2 hrs before the addition of bax siRNA-functionalized OVA
hydrogel nanoparticles, unfunctionalized hydrogel nanoparticles, bax siRNA or poly(I:C).
The highest final concentration of bax siRNA used was 4 gM. bax siRNA-functionalized
nanoparticles were added such that the effective concentrations of bax siRNA delivered
along with the nanoparticles were 1/10 those of the soluble bax siRNA controls. Thus,
the highest final concentration of bax siRNA delivered on the hydrogel nanoparticles was
400 nM. Control unfunctionalized nanoparticles were added such that their final
concentrations matched those of the bax siRNA-functionalized nanoparticles. All
samples were incubated for 24 hrs, upon which the culture supernatants were analyzed
for IFN-a, a key marker of DC activation.
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3 Results and Discussion
3.1 Hydrogel nanoparticle synthesis
Pluronic® polyoxyethylene-polyoxypropylene-polyoxyethylene (PEO-PPO-PEO) triblock
copolymers are known to form micelles when present in aqueous solutions above their
critical micelle concentrations (CMCs) and critical micelle temperatures (CMTs) [23].
The PEO blocks of the Pluronic® polymer dehydrates at high temperatures. Above the
CMT, phase separation occurs, resulting in polymer-rich and polymer-poor phases. The
E0 78-PO 30 -EO78 Pluronic® F-68 triblock is relatively hydrophilic compared to others in
the Pluronic® family of copolymers, with an extrapolated CMT of -105°C in water [24].
It is also known that the CMTs of the Pluronics® are strongly influenced by the presence
of monovalent salts. This is thought to be due to repulsion between small, weakly
polarizable ions and the weakly polarizable PEO blocks, an effect also observed for PEO
homopolymers in salt solutions [24] - [26]. Bahadur et al. have shown that the cloud
point of Pluronic® F-68 can be lowered by 50°C upon addition of KF to a final
concentration of 1 M [24]. Similarly, we found that the CMT of Pluronic® F-68 could be
lowered to -37°C in a 5.5 M NaCl solution. Figure 1 shows dynamic light scattering data,
where the measured hydrodynamic diameter of Pluronic® F-68 aggregates in an aqueous
solution of 4% w/v Pluronic® F-68 and 5.5 M NaCl increased from -35 nm at 320 C to
-400 nm at 37C, coincident with obvious clouding of the initially clear solution (Jain, S.
data submitted).
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Figure 1: Mean diameter of Pluronic® F-68 aggregates as a function of temperature in 4%
w/v Pluronic® F-68 aqueous solutions containing 5.5 M NaCI with (o) and without ()
the addition of 1 mg/mL OVA and 6.6 mg/mL monomers (6 mg/mL PEGMA, 0.3
mg/mL PEGDMA, 0.3 mg/mL MAA).
Peppas and co-workers had also reported the successful suspension polymerization of
PEGMA homopolymer in a saturated aqueous NaCl solution, based on the salting-out of
PEGMA monomers [27]. This report, coupled with the known phase separation behavior
of Pluronic® F-68 in aqueous salt solutions, prompted us to combine the temperature-
induced phase separation of Pluronic® F-68 in salt solution with the well-known salting-
out behavior of both PEO and proteins in high ionic strength solutions, in order to co-
localize protein and hydrogel precursor monomers together for polymerization in an
organic solvent-free system, as illustrated in Figure 2 [28], [29].
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Figure 2: Diagram illustrating the proposed mechanism of particle synthesis and
functionalization with CpG 1826 oligonucleotides or bax siRNA.
A model protein antigen, OVA, and the hydrogel precursor monomers PEGMA,
PEGDMA, and MAA were added to a 4% w/v aqueous solution of Pluronic® F-68 and
5.5M NaCI. Heating of the solution to 40°C followed by addition of the free radical
initiator APS/SMS led to the rapid polymerization of monomers within the
protein/polymer-rich phase of the emulsion. The hydrogel nanoparticles thus formed
were then recovered by centrifugation of the resulting suspension. Dynamic light
scattering showed that these particles had diameters of 490 30 nm. A histogram
representative of multiple experiments is shown in Figure 3 (Jain, S. data in submitted).
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Figure 3: Histogram showing the size distribution of hydrogel nanoparticles as measured
by dynamic light scattering.
3.2 CpG 1826 oligonucleotide and bax siRNA functionalization
In order to elicit a protective T cell response, vaccines need to deliver both antigen and an
activating 'danger' signal to DCs. This triggers the differentiation of DCs from an
otherwise 'immature' antigen-collecting state to a 'mature' antigen-presenting and T cell
activating state [7]. We have chosen to provide such an activation signal either via single
stranded CpG oligonucleotides or via double-stranded bax siRNA molecules bound to the
surface of our hydrogel nanoparticles. Single-stranded CpG oligonucleotides, known
ligands for Toll-like receptor 9 (TLR9), are known to promote robust DC maturation and
activation while siRNA molecules activate DCs via Toll-like receptor 3 (TLR3) [18],
28
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[20]. These DC-activating danger signals were attached to the surfaces of the
nanoparticles by a two-step electrostatic self-assembly process as shown in Figure 2.
First, poly(L-arginine) was adsorbed to the anionic methacrylic acid-containing hydrogel
particles to obtain a positively-charged particle surface, followed by electrostatic
adsorption of the negatively-charged CpG oligonucleotides or bax siRNA. Typical
amounts of CpG oligonucleotides and bax siRNA added to the particles which were
adsorbed were on the order 97% to 98%. Figure 4 illustrates the binding efficiency of
bax siRNA as a function of siRNA added to 5 mg/mL poly(L-arginine)-coated
nanoparticles.
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Figure 4: Plot of adsorption efficiency as a function of the original bax siRNA
concentration at the start of the incubation period.
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3.3 Encapsulated ovalbumin release by cathepsin D digestion
A robust immune response is dependent on appropriate DC activation and priming of T
cells. Within DCs, there exist lysosomes and phagolysosomes, intracellular processing
compartments, where a host of degradative enzymes are localized to digest proteins into
short polypeptides that can be loaded onto class I and class II major histocompatibility
complex molecules and shuttled to the cell surface for physical presentation to T cells.
This presentation of antigen to T cells, along with other co-stimulatory signals, then
primes T cells to recognize specific protein antigens.
We hypothesized that encapsulation of protein in a hydrogel network would selectively
allow DC proteolytic enzymes with sizes smaller than the mesh size of the gel particle
network to directly diffuse into the network and cleave entrapped protein antigen. The
native antigen presentation machinery of the DC would then process the resulting peptide
fragments that diffuse out of the gel particle. To test this hypothesis, we incubated the
ova-loaded gel particles with cathepsin D (CatD) in vitro. CatD is a ubiquitous protease
involved in antigen processing in the endosomes/phagosomes of antigen presenting cells
and is known to digest OVA [30], [31 ].
CpG-modified, OVA-loaded hydrogel particles were incubated at pH 5.5 (mimicking the
pH of endolysosomal compartments) with CatD for 48 hrs, and the supernatant from this
co-incubation was then analyzed for the presence of protein/peptide fragments by size
exclusion chromatography. The resultant chromatogram (Figure 5A) showed the
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production of fragments ranging in approximate molecular size from 2-30 kDa, and was
comparable to that observed for soluble OVA digestion by CatD (Figure 5B). The
supernatant from particle digestion was clearly demarcated from controls containing
CatD alone (Figure 5C) or undigested OVA, and no peptide fragments were detected in
the supernatant of OVA particles incubated in the absence of the CatD enzyme. In the
absence of specific protease treatment, ova was stably encapsulated - < 5% of the
encapsulated protein was released after incubation of gel particles in serum-containing
medium at 37°C for one week.
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Figure 5: Size exclusion chromatograms of supernatants from 48 hrs incubation of (A)
200 [tg/mL CatD with 5 mg/mL CpG-modified OVA hydrogel nanoparticles, (B) 200
gg/mL CatD with 5 mg/mL OVA and (C) CatD alone.
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3.4 Particle uptake by dendritic cells
DCs are known to be highly efficient phagocytes that can rapidly internalize submicron-
sized biological and synthetic particles [22]. In order to determine if our gel
nanoparticles were phagocytosed by DCs, murine DCs were incubated with fluorescent
DQ-OVA-loaded hydrogel nanoparticles as described and imaged using fluorescence
microscopy. The left panel of Figure 6 shows the uptake of DQ-OVA-loaded
nanoparticles by DCs relative to the control in the right panel.
Figure 6: Hydrogel nanoparticle uptake by DCs. DCs that had been incubated with DQ-
OVA-loaded hydrogel nanoparticles show intracellular fluorescence (left panel) while
DCs that had been incubated in control medium without any nanoparticles show no
fluorescence (right panel).
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3.5 Analysis of dendritic cell maturation by IL12-p40/p70 ELISA
To measure the efficacy of CpG-coated hydrogel nanoparticles to induce DC activation
and maturation, DCs were prepared as described in Section 2.6 and incubated for 48 hrs
with CpG oligonucleotide-functionalized nanoparticles, soluble CpG oligonucleotide
control and particles that had not been coated with any CpG oligonucleotide. The
supernatants of the resultant cell cultures were then analyzed by ELISAs for the 2
subunits of the IL-12 cytokine, p40 and p70. The secretion of IL-12 is commonly used as
a marker for DC maturation [7]. Figures 7 and 8 show that CpG-coated hydrogel
nanoparticles induce potent activation and maturation of DCs relative to soluble CpG
oligonucleotide and uncoated particles.
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Figure 7: IL-12p40 secretion levels, as measured by ELISA, when DCs were incubated
with CpG oligonucleotide-functionalized particles, soluble CpG oligonucleotide and
uncoated particles.
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Figure 8: IL-12p70 secretion levels, as measured by ELISA, when DCs were incubated
with CpG oligonucleotide-functionalized particles, soluble CpG oligonucleotide and
uncoated particles.
3.6 Analysis of dendritic cell activation by IFN-a ELISA
To compare the DC activation response triggered by CpG oligonucleotides, which signals
through TLR9, with that triggered by RNA-based ligands, which signal through TLR3,
we fabricated siRNA-functionalized hydrogel nanoparticles and analyzed them for their
capacity to induce and activate the interferon system in DCs, in particular IFN-a. Both
poly(I:C) and siRNA are known to induce IFN-a secretion in DCs [17]. IFN-a
synergizes with other proinflammatory cytokines to activate innate and adaptive immune
effector cells [18]. IFN-a also causes cells to enter into an "anti-viral" state, thus aiding
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in the fight against viral and bacterial infections [19]. Furthermore, IFN-a secretion
might also stimulate DCs in an autocrine manner to further induce their maturation and
activation. We have thus fabricated bax siRNA-functionalized nanoparticles in order to
achieve co-delivery of antigen with an IFN-a inducing signal. DCs were prepared as
described in Section 2.6 and incubated for 24 hrs with siRNA-functionalized
nanoparticles, particles that had not been coated with any CpG oligonucleotide, soluble
siRNA control and soluble poly(I:C) control. The supematants of the resultant cell
cultures were then analyzed by ELISAs for IFN-a. Figure 9 show that siRNA-coated
hydrogel nanoparticles induce potent IFN-a secretion by DCs relative to soluble siRNA,
soluble poly(I:C) and uncoated particles.
It is interesting to note that poly(L-arginine)-coated particles elicited a vigorous IFN-a
response, relative to soluble siRNA and soluble poly(I:C). In fact, at low nanoparticle
concentrations, poly(L-arginine)-coated particles induced a greater level of IFN-a
secretion than siRNA-coated particles. We propose that the poly(L-arginine)-coated
particles were cytotoxic, inducing the DCs to enter a state of 'shock' and activating the
interferon system. Nonetheless, at the highest concentrations of siRNA-functionalized
nanoparticles tested, there is significant activation of the DCs. As shown in Figure 9,
siRNA-functionalized nanoparticles resulted in -10-fold greater secretion of IFN-a as
compared to the positive control, poly(I:C).
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Figure 9: IFN-a secretion levels, as measured by ELISA, when DCs were incubated bax
siRNA-functionalized particles, soluble siRNA, soluble poly(I:C) and uncoated particles.
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4 Future Work
4.1 Knock-down of the Bcl-2 apoptosis pathway
21 base-pair double-stranded siRNAs which have traditionally been used to induce
specific gene silencing have recently been noted to activate the interferon system in a
large variety of cells [32]. siRNAs have been extensively used to modulate DC function
for a variety of purposes. In particular, siRNA-mediated inhibition of suppressor of
cytokine signaling-1 (SOCS1) in murine DCs has been found to enhance the
immunostimulatory capacity of DCs [33]. Furthermore, modification of professional
APCs, especially DCs, with siRNA in vivo has been shown to enhance cancer vaccine
potency [34]. Kim et al. used siRNA targeting the key proapoptotic genes bak and bax to
prolong the lives of antigen-presenting DCs in the draining lymph nodes and found that
antigen-specific CD8+ T-cell responses were enhance [34].
We knew that the Bcl-2 pathway was an important mechanism for apoptosis in DCs and
had the similar idea of silencing the bax gene in DCs in order to improve the
immunogenicity of our vaccine [35]. This was the main impetus for deciding to
functionalize our hydrogel nanoparticles with an siRNA against the bax gene. Due to
time constraints, we were unable to perform bax knockdown experiments to determine
the efficacy of our prototype with regard to prolonging the lifespan of antigen-expressing
DCs. This would constitute one of the areas for future work. To simplify the analysis of
siRNA-driven gene silencing, one could make use of DCs expressing the enhanced green
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fluorescent protein (EGFP) and treat them with anti-EGFP siRNA-functionalized
nanoparticles.
4.2 Endosomal leakage of particles
Another area of future research would comprise of determining the endosomal leakage of
siRNA-functionalized particles and unfunctionalized particles into the cytosol. The
interaction of siRNA with TLR3 has not been fully studied in terms of endosomal
trafficking of the TLR3 ligand. It would be interesting to observe if siRNA interaction
with TLR3 triggers the endosomal leakage/escape of particles into the cytosol. To this
end, one can either make use of siRNA that had been labeled with a fluorescent tag or
load siRNA-functionalized particles along with calcein into DCs and then observing (by
fluorescence microscopy) for either punctate or diffuse fluorescent within the DCs [36].
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5 Conclusions
The lack of suitable vaccines for currently incurable diseases such as hepatitis C and HIV
have provided an impetus for the development of new approaches to vaccine formulation.
In particular, recombinant protein subunits and synthetic peptides offer significant
advantages over the traditional vaccines in terms of safety and reduced toxicity.
However, their use has been impeded by the lack of suitable delivery methods and
adjuvants. We have synthesized hydrogel nanoparticles that can encapsulate protein
antigens with high efficiency and protein loading. In addition, we have shown in vitro
that these nanoparticles are readily taken up by DCs and that the encapsulated protein
antigen is readily accessible to the endolysosomal enzyme, cathepsin D. DC maturation
and activation by CpG oligonucleotide-functionalized and siRNA-functionalized
nanoparticles was determined by ELISAs for IL-12 and IFN-a and found to be
significantly higher than the respective controls. There is much future work to be done in
terms of modulating DC behavior and function using various siRNAs and the
investigation of the transport pathway of siRNA-functionalized nanoparticles. In
conclusion, we have successfully fabricated a prototype that is capable of efficient co-
delivery of protein antigen and DNA/RNA adjuvants.
39
7 References
[1] Marciani, D. J. Drug Discovery Today 2003, 8(20), 934-943.
[2] Singh, M. & O'Hagan D. Nature Biotech. 1999, 17, 1075-1081.
[3] Jenner, E. The Harvard Classics 1910, 38(4), 149-231, P.F. Colier & Son, New
York.
[4] Ramon, G. Ann. Inst. Pasteur 1924, 38, 1-10.
[5] Gupta, R.K. Adv. Drug Delivery Reviews 1998, 32, 155-172.
[6] Relyveld, E.H., Bizzini, B., Gupta, R.K. Vaccine 1998, 16, 1016-1023.
[7] Banchereau, J. & Steinman, R.M. Nature 1998, 392, 245-252.
[8] Steinman, R.M. in Fundamental Immunology 4 th Ed. Lippincott-Raven,
Philadelphia
[9] Cella, M. et al. J. Exp. Med. 1996, 184, 747-752.
[10] Koch, F. et al. J. Exp. Med. 1996, 184, 741-757.
40
[11] Caux, C. et al. J. Exp. Med. 1994, 180, 1263-1272.
[12] Inaba, K. et al. J. Exp. Med. 1992, 176, 1693-1702.
[13] Medzhitov, R. Nature Rev. Immunol. 2001, 135, 135-145.
[14] O'Neill L.A.J. Science 2004, 303, 1481-1482.
[15] Cella, M. et al. J. Exp. Med. 1999, 189(5), 821-829.
[16] Kamath, A.T. et al. JImmunol. 2005, 174, 767-776.
[17] Diebold, S. et al. Nature 2003, 424, 324-328.
[18] Tough, D.F. etal. Science 1996, 272, 1974-1950.
[19] Marrack, P. et al. J. Exp. Med. 1999, 189, 521-530.
[20] Krieg, A.M. Annu. Rev. Immunol. 2002, 20, 709-760.
[21] Gursel, I. etal. J. Immunol. 2001, 167, 3324-3328.
[22] Shen, Z.H. et al. J. Immunol. 1997, 158, 2723-2730.
41
[23] Nace, V.M. Nonionic surfactants: polyoxoalkylene block copolymers, 1996 M.
Dekker, New York
[24] Bahadur, P. et al. Langmuir 1992, 8, 1903-1907.
[25] Jain, N.J. et al. Colloid Surface A 2000, 173, 85-94.
[26] Florin, E. et al. J Chem Soc Farad T 1 1984, 80, 2889-2910.
[27] Drummond, R.K. et al. Macromolecules 1989, 22, 3816-3818.
[28] Guermant, C. et al. Anal. Biochem. 1995, 230, 254-258.
[29] Shih, Y.C. et al. Biotechnol. Bioeng. 1992, 40, 1155-1164.
[30] Diment, S. JImmunol 1990, 145, 417-422.
[31] Rodriguez, G. M. et. al. Jlmmunol 1992, 149, 2894-2898.
[32] Sledz, C.A. et al. Nature Cell Biology 2003, 5(9), 834-839.
[33] Shen, L. Nature Biotech. 2004, 22(12), 1546-1553.
42
[34] Kimn, T.W. Cancer Res. 2005, 65(1), 309-316.
[35] Moser, M. Nature Immunology 2004, 5(6), 559-560.
[36] Jones, R.A. et al. Biochem. J. 2003, 372, 65-75.
43
